These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 20389255)

  • 1. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
    Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
    Pandina G; Lane R; Gopal S; Gassmann-Mayer C; Hough D; Remmerie B; Simpson G
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):218-26. PubMed ID: 21092748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
    Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M
    Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
    Hough D; Lindenmayer JP; Gopal S; Melkote R; Lim P; Herben V; Yuen E; Eerdekens M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1022-31. PubMed ID: 19481579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
    Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
    Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
    Vieta E; Nuamah IF; Lim P; Yuen EC; Palumbo JM; Hough DW; Berwaerts J
    Bipolar Disord; 2010 May; 12(3):230-43. PubMed ID: 20565430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
    Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D
    Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.